Five drug classes account for over 80% of all medication-induced SIADH cases: antidepressants, anticonvulsants, chemotherapy agents, antipsychotics, and pain medications. SIADH (syndrome of inappropriate antidiuretic hormone) happens when a drug triggers your body to release too much of the hormone that controls water balance, causing your kidneys to hold onto excess water and dilute your blood sodium to dangerously low levels.
Antidepressants: The Most Common Cause
Antidepressants are responsible for roughly one-third of all drug-induced SIADH cases, making them the single largest category. Both SSRIs and SNRIs work by increasing serotonin activity in the brain, but that same serotonin boost activates receptors in the hypothalamus that stimulate the release of antidiuretic hormone (ADH). More ADH means your kidneys reabsorb more water, diluting your sodium.
About 6% of people taking an SSRI or SNRI develop some degree of low sodium. For most, the drop is mild and causes no symptoms. Clinically significant low sodium occurs in roughly 1% of SSRI users and 1.3% of SNRI users. Among individual drugs, fluoxetine and venlafaxine carry the highest risk, while sertraline and duloxetine are associated with lower rates.
The danger window is predictable. Low sodium from a psychotropic medication typically appears within two to four weeks of starting the drug or after a significant dose increase. If the medication is stopped, sodium levels usually return to normal within 2 to 28 days.
Anticonvulsants: Carbamazepine and Oxcarbazepine
Anticonvulsants are the second most common drug class linked to SIADH, involved in about 21% of cases. Two medications stand out: carbamazepine and oxcarbazepine, both used for epilepsy, trigeminal neuralgia, and bipolar disorder. These drugs appear to stimulate a receptor in the kidneys that increases water reabsorption, effectively mimicking the action of ADH rather than triggering its release from the brain.
The rates of low sodium with these drugs are striking. Reported estimates range from 4% to 40% for carbamazepine and 23% to 73% for oxcarbazepine, with oxcarbazepine consistently carrying the higher risk. In one analysis, 78% of people who developed low sodium on oxcarbazepine experienced adverse effects from it, compared with 59% on carbamazepine. If you’re prescribed either medication, your doctor will likely monitor your sodium levels periodically, especially in the first few months.
Chemotherapy Agents
Several cancer drugs cause SIADH, though each works through a different mechanism. Vincristine (and to a lesser extent vinblastine) disrupts normal sodium sensing by damaging nerve pathways between the brain and pituitary gland, a neurotoxic effect that throws off the body’s ability to regulate ADH release. Cyclophosphamide amplifies ADH’s action in the kidneys and may also increase ADH secretion directly. This creates a particular problem because patients on cyclophosphamide are told to drink large amounts of fluid to protect the bladder, which can worsen water retention. Cisplatin stimulates ADH secretion but can also damage kidney tubules directly, creating a double threat to sodium balance.
Managing SIADH in cancer patients is especially tricky. The standard first-line approach for SIADH is fluid restriction, but patients receiving cisplatin need to stay well hydrated to prevent kidney damage. Persistent low sodium during chemotherapy is also linked to poorer outcomes: patients whose sodium fails to normalize by the second treatment cycle tend to have worse survival.
Antipsychotics and Pain Medications
Antipsychotic medications account for about 11% of drug-induced SIADH cases. Both older (typical) and newer (atypical) antipsychotics have been implicated. The mechanism overlaps with antidepressants, as many antipsychotics also affect serotonin signaling.
Pain medications contribute about 10% of cases. This category includes opioids, which can directly stimulate ADH release, and NSAIDs, which work through a different pathway. NSAIDs block the production of a prostaglandin that normally puts the brakes on ADH activity. By removing that brake, NSAIDs allow ADH to work more powerfully in the kidneys, even without increasing the amount of hormone being released. NSAID-related cases tend to develop over longer periods of use, particularly in people who already have other risk factors for low sodium.
Less Common Triggers
Proton pump inhibitors (PPIs) like omeprazole and lansoprazole have been linked to SIADH, though the evidence is more limited. The risk appears greatest when the medication is first started and in older adults taking them long-term (over one year). Omeprazole has the most reported cases. The exact mechanism isn’t fully understood, but the pattern of lab findings in affected patients, including concentrated urine and normal fluid volume, points toward inappropriate ADH release.
Other medications that have been associated with SIADH in case reports include desmopressin (a synthetic version of ADH used for bedwetting and diabetes insipidus), certain antibiotics, and the recreational drug MDMA (ecstasy), which both stimulates ADH release and encourages excessive water intake.
Who Is Most at Risk
The drug alone doesn’t tell the whole story. Certain people are far more vulnerable to developing SIADH from a medication. Older adults top the list because aging kidneys are less efficient at excreting excess water. Women are at higher risk than men, particularly older women with low body weight. Taking multiple medications that affect sodium, such as combining an SSRI with a thiazide diuretic, compounds the risk significantly. Low potassium levels also make the problem more likely.
For SSRIs specifically, older age and concurrent diuretic use are the two strongest predictors. This is worth knowing because SSRIs are commonly prescribed to older adults for depression and anxiety, and many of those same patients are already on a diuretic for blood pressure.
What SIADH Feels Like and How It Resolves
Mild SIADH can be silent. You might feel slightly off, perhaps more fatigued or a little foggy, but attribute it to the underlying condition being treated. As sodium drops further, symptoms become harder to ignore: nausea, headaches, confusion, muscle cramps, and unsteadiness. Severe cases can cause seizures or loss of consciousness.
The condition often develops insidiously over days or weeks, which is part of what makes it easy to miss. If a causative drug is identified, stopping it is usually the first step. For mild cases, limiting fluid intake to reduce the dilution effect is the standard approach, though this only works in about half of patients. When fluid restriction isn’t enough, medications that block ADH’s effect on the kidneys can help restore sodium levels. The key is correcting sodium gradually, because raising it too quickly carries its own serious neurological risks.
For people who need to stay on a medication that causes SIADH, such as an anticonvulsant controlling seizures or a chemotherapy drug treating cancer, long-term management with lower doses of ADH-blocking medication has shown good results. In epilepsy patients, normalizing sodium levels has been linked to better seizure control and fewer symptoms overall.